Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Momenta Pharmaceuticals Inc (MNTA) Com Stk USD0.0001

Sell:$33.80 Buy:$33.81 Change: $0.16 (0.47%)
NASDAQ:1.79%
Market closed |  Prices as at close on 21 February 2020 | Switch to live prices |
Sell:$33.80
Buy:$33.81
Change: $0.16 (0.47%)
Market closed |  Prices as at close on 21 February 2020 | Switch to live prices |
Sell:$33.80
Buy:$33.81
Change: $0.16 (0.47%)
Market closed |  Prices as at close on 21 February 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.

Contact details

Address:
301 Binney St
CAMBRIDGE
02142-1030
United States
Telephone:
+1 (617) 4919700
Website:
www.momentapharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
MNTA
ISIN:
US60877T1007
Market cap:
$3.91 billion
Shares in issue:
115.72 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Craig Wheeler
    President, Chief Executive Officer, Director
  • Young Kwon
    Chief Financial and Business Officer
  • Jo-Ann Beltramello
    Chief Human Resources and Infrastructure Officer
  • Agnieszka Cieplinska
    Principal Accounting Officer
  • Anthony Manning
    Chief Scientific Officer
  • Alejandra Carvajal
    Chief Legal Officer, General Counsel and Secretary
  • Santiago Arroyo
    Chief Medical Officer
  • Ian Fier
    Chief Manufacturing and Program Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.